Literature DB >> 18631007

A new germline point mutation in Ret exon 8 (cys515ser) in a family with medullary thyroid carcinoma.

Francesca Fazioli1, Gina Piccinini, Gloria Appolloni, Roberta Bacchiocchi, Gioia Palmonella, Rina Recchioni, Elisa Pierpaoli, Francesca Silvetti, Marina Scarpelli, Matteo Bruglia, Rosa Marina Melillo, Massimo Santoro, Marco Boscaro, Augusto Taccaliti.   

Abstract

BACKGROUND: A novel Cys-Ser Ret germline point mutation in a 58-year-old woman with bilateral medullary thyroid carcinoma (MTC) prompted us to perform genetic analysis of the family and evaluate the biological consequences of such a mutation.
METHODS: Ret analysis by direct sequencing was performed in five family members. The biological activity and biochemical properties of the Ret- Cys515Ser mutant were analyzed in NIH-3T3 cells.
RESULTS: The proband's son, age 35, had the Ret- Cys515Ser mutation and the L769 CTT/CTG exon 13 polymorphic variant, which was also found in his father. Clinical evaluation of the son also revealed bilateral multifocal microscopic MTC and papillary thyroid carcinoma (PTC). In vitro and in vivo analysis indicated ligand-independent activation of the Ret-Cys515Ser mutant due to aberrant disulfide homodimerization, increased mitogenic activity, and ability to induce anchorage-independent growth in NIH-3T3 cells in comparison to wild-type Ret, suggesting a possible role of Cys515Ser in tumor development.
CONCLUSIONS: The Cys515Ser mutation adds to cysteine substitution groups that have been described in association with MTC. Our data also highlight the importance of performing a complete genetic analysis in patients who present with MTC.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18631007     DOI: 10.1089/thy.2007.0365

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  8 in total

1.  Identification and characterization of two novel germline RET variants associated with medullary thyroid carcinoma.

Authors:  A L Silva; F Carmo; M M Moura; R Domingues; C Espadinha; V Leite; B Cavaco; M J Bugalho
Journal:  Endocrine       Date:  2015-03-01       Impact factor: 3.633

Review 2.  Hereditary medullary thyroid carcinoma: the management dilemma.

Authors:  Ping Zhou; Jian Liu; Shao-Wen Cheng; Bing Wang; Rong Yang; Ling Peng
Journal:  Fam Cancer       Date:  2012-06       Impact factor: 2.375

Review 3.  Central role of RET in thyroid cancer.

Authors:  Massimo Santoro; Francesca Carlomagno
Journal:  Cold Spring Harb Perspect Biol       Date:  2013-12-01       Impact factor: 10.005

4.  Genetic alterations in medullary thyroid cancer: diagnostic and prognostic markers.

Authors:  Taccaliti A; Silvetti F; Palmonella G; Boscaro M
Journal:  Curr Genomics       Date:  2011-12       Impact factor: 2.236

5.  RET mutation p.S891A in a Chinese family with familial medullary thyroid carcinoma and associated cutaneous amyloidosis binding OSMR variant p.G513D.

Authors:  Xiao-Ping Qi; Jian-Qiang Zhao; Zhen-Guang Chen; Jin-Lin Cao; Juan Du; Nai-Fang Liu; Feng Li; Mao Sheng; Er Fu; Jian Guo; Hong Jia; Yi-Ming Zhang; Ju-Ming Ma
Journal:  Oncotarget       Date:  2015-10-20

6.  Familial MTC with RET exon 8 Gly533Cys mutation: origin and prevalence of second malignancy.

Authors:  Katerina Saltiki; Elli Anagnostou; George Simeakis; Sofia Kouki; Anastasia Angelopoulou; Leda Sarika; Alexandra Papathoma; Maria Alevizaki
Journal:  Endocr Connect       Date:  2017-09-26       Impact factor: 3.335

7.  The optimal range of RET mutations to be tested: European comments to the guidelines of the American Thyroid Association.

Authors:  Laura Fugazzola; Simone De Leo; Michela Perrino
Journal:  Thyroid Res       Date:  2013-03-14

Review 8.  Multiple endocrine neoplasia type 2: achievements and current challenges.

Authors:  Andreas Machens; Henning Dralle
Journal:  Clinics (Sao Paulo)       Date:  2012       Impact factor: 2.365

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.